LifeMax Laboratories, Inc. today announced an exclusive worldwide license from Novartis Pharma AG for the right to develop, manufacture and commercialize BPR277, a clinical stage asset with positive clinical proof of concept for the treatment of Netherton Syndrome.
August 27, 2018
· 2 min read